Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $536.70 USD
Change Today -1.30 / -0.24%
Volume 507.8K
REGN On Other Exchanges
Symbol
Exchange
Munich
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - regeneron pharmaceuticals (REGN)

Name (Connections)Board RelationshipsTitleKey Developments
George Sing 17 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Compensation Committee 
Charles Baker J.D. 11 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee 
Arthur Ryan 84 RelationshipsIndependent Director, Member of Audit Committee and Member of Corporate Governance & Compliance Committee 

Compensation Committee* - regeneron pharmaceuticals (REGN)

Name (Connections)Board RelationshipsTitle
Charles Baker J.D. 11 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee
Joseph Goldstein M.D. 109 RelationshipsIndependent Director, Member of Compensation Committee and Member of Technology Committee
Robert Ingram 213 RelationshipsDirector and Member of Compensation Committee
Christine Poon 48 RelationshipsIndependent Director, Member of Compensation Committee and Member of Corporate Governance & Compliance Committee
George Sing 17 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Compensation Committee
Marc Tessier-Lavigne Ph.D. 76 RelationshipsIndependent Director, Chairman of Compensation Committee and Member of Technology Committee
REGN Compensation vs. Industry
1.1M
354.4K
Chief Executive Officer
500.0K
262.5K
Chief Financial Officer
Share price activity for REGENERON PHARMACEUTICALS (REGN)
52 Week Price Performance
REGN
Industry Average

Corporate Governance Committee* - regeneron pharmaceuticals (REGN)

Name (Connections)Board RelationshipsTitle
Michael Brown M.D. 25 RelationshipsIndependent Director, Member of Audit Committee and Member of Compensation Committee
Alfred Gilman M.D., Ph.D. 11 RelationshipsIndependent Director, Member of Compensation Committee and Member of Technology Committee
Christine Poon 48 RelationshipsDirector and Member of Compensation Committee
Arthur Ryan 84 RelationshipsIndependent Director, Member of Compensation Committee and Member of Corporate Governance & Compliance Committee
REGN and Competitor
Insiders vs. External
Board
25%
75%
Regeneron Pharmaceuticals, Inc.
6%
94%
BioMarin Pharmaceutical Inc.
22%
78%
Vertex Pharmaceuticals Incorporated
14%
86%
Incyte Corporation
38%
62%
Kyowa Hakko Kirin Co., Ltd.
4%
96%
UCB S.A.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $536.70 USD -1.30

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $133.18 USD +2.29
Incyte Corp $119.93 USD +6.08
Kyowa Hakko Kirin Co Ltd ¥2,065 JPY +53.00
UCB SA €67.53 EUR -0.23
Vertex Pharmaceuticals Inc $134.05 USD +0.30
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 100.0x
Price/Sales 16.3x
Price/Book 16.5x
Price/Cash Flow 122.6x
TEV/Sales 16.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.